Aim: To evaluate treatment patterns and overall survival (OS) in real world metastatic non-squamous non-small-cell lung cancer (NSQ-NSCLC) patients that received pembrolizumab plus pemetrexed-platinum (pembro+pem+plat) aligned with KEYNOTE-189. Materials & methods: OS was evaluated for the overall cohort and maintenance therapy (MT) subgroups and analyzed using Kaplan-Meier estimates and Cox proportional hazards model. Results: Of 2488 patients that received first-line treatment, 45.1% received less than four cycles of pembro+pem+plat, 43.9% received four cycles plus MT with pembro and/or pem, and 11.1% received four cycles without continuing on MT. The median OS was 21.0 months and 9.1 months in patients that continued and did not continue MT. Conclusion: Real world patients that received KEYNOTE-189-aligned treatment had similar OS benefits.
Objectives: To evaluate the cost-effectiveness of pembrolizumab plus axitinib compared with sunitinib for first-line treatment of advanced renal cell carcinoma from a third-party payer perspective in the U.S. Methods: A Markov model with a cycle length of 6 weeks was constructed to simulate three health states: progressionfree, progressive disease and death. The model was run until 99% patients died. Both health outcomes and costs were discounted at an annual rate of 3%. Clinical parameters were informed by the KEYNOTE-426 trial. Cost data including drug acquisition costs, administration costs and adverse event costs were derived from government reimbursement schedules and published literature and adjusted to 2019 USD. Utility values of different health states and disutility from adverse events were obtained from published literature. Outcomes were measured as incremental costeffectiveness ratios (ICERs) and net monetary benefits (NMBs). One-way sensitivity analysis was performed to test the robustness of the model. Results: In the base case, pembrolizumab plus axitinib generated a gain of 3.25 life years (5.11 vs. 1.86) and 1.35 quality-adjusted life years (QALYs) (3.03 vs. 1.68
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.